Evan Y. Yu, MD, discusses the utility of enfortumab vedotin-ejfv in patients with locally advanced or metastatic urothelial cancer.
Evan Y. Yu, MD, clinical research director, Genitourinary Medical Oncology, Seattle Cancer Care Alliance, professor of medical oncology, University of Washington School of Medicine, professor in the clinical research, Fred Hutchinson Cancer Research Center, medical director, clinical research support, Fred Hutchinson Cancer Research Consortium, discusses the utility of enfortumab vedotin-ejfv (Padcev) in patients with locally advanced or metastatic urothelial cancer.
Enfortumab vedotin has elicited a significant overall survival (OS) benefit when administered in the third-line setting for this patient population, according to recent data published in the New England Journal of Medicine. Therefore, following avelumab (Bavencio) maintenance therapy, enfortumab vedotin can be used as a default agent in this setting, according to Yu.
Additionally, erdafitinib (Balversa) can be utilized in patients who have an FGFR alteration, although it is easy to gravitate toward enfortumab vedotin due to the level 1 evidence and OS benefit that has been demonstrated with agent, Yu concludes.